Orçun Haçariz

Dr. Orçun Haçariz


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
OHOrçun Haçariz
Orçun Haçariz
Charles ViauCharles Viau
Charles Viau
XGXue Gu
Xue Gu
Jianguo XiaJianguo Xia
Jianguo Xia
The roles of the healthy microbiome on the host and the relationships between members of the microbiome remain to be fully characterized. Due to the complexity of the interactions between the mammalian microbiome and its host, the use of model organisms such as the nematode worm Caenorhabditis elegans is a promising strategy to study host-microbiome interactions in vivo, as well as bacterial crosstalk within the host. Previously it was found that native bacterial isolates of the worm, Chryseobacterium sp. CHNTR56 MYb120 and Comamonas sp. 12022 MYb131, possess genomic diversity in the biosynthesis of the active form of vitamin B6, pyridoxal 5′-phosphate (PLP), and contribute to host fitness and lifespan extension. However, the relative contribution of PLP from each isolate, as well as the existence of interbacterial relationships within the worm gut remain to be characterized. In the present work, we investigated the presence and measured the abundance of PLP in the isolates and in the worms grown with the isolates using ultraperformance liquid chromatography tandem-mass spectrometry (UPLC-MS/MS). Our analyses confirmed the presence of PLP in vitro and in vivo. The elevated abundance of PLP in the isolates (which reached statistically significant levels when the two isolates were combined), and within worms grown with the combination of bacterial isolates, compared to control, indicated synergism between the isolates in the production of PLP. Isotope labeling revealed that Comamonas sp. 12022 MYb131 was the main provider of PLP in worms grown with the combination of bacterial isolates. The dominance of this isolate inside the worm was further confirmed by a colonization assay. An untargeted metabolomics analysis of the bacteria showed that the pathways related to cell growth, protein synthesis and lipid synthesis/energy production were regulated in the combination group in comparison with Comamonas sp. 12022 MYb131 alone. Furthermore, glutamine, involved in the de novo synthesis of purine and pyrimidines, was specifically abundant in this group, indicating the potential role of this metabolite in initiating and sustaining bacterial growth. This bacterial crosstalk is suggested to promote the growth of Comamonas sp. 12022 MYb131 in vivo, and synthesis of bacterial metabolites such as PLP in the worm gut.

28 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SPStephanie Perrino
Stephanie Perrino
UVUdi Vazana
Udi Vazana
OPOfer Prager
Ofer Prager
LSLior Schori
Lior Schori
GBGal Ben-Arie
Gal Ben-Arie
PBPnina Brodt
Pnina Brodt
Background: Glioblastoma multiforme is an aggressive malignancy with a dismal 5-year survival rate of 5–10%. Current therapeutic options are limited, due in part to drug exclusion by the blood–brain barrier (BBB). We have previously shown that high-amplitude repetitive transcranial magnetic stimulation (rTMS) in rats allowed the delivery across the BBB of an IGF signaling inhibitor—IGF-Trap. The objective of this study was to assess the therapeutic effect of IGF-Trap when delivered in conjunction with rTMS on the intracerebral growth of glioma. Results: We found that systemic administration of IGF-Trap without rTMS had a minimal effect on the growth of orthotopically injected glioma cells in rats and mice, compared to control animals injected with vehicle only or treated with sham rTMS. In rats treated with a combination of rTMS and IGF-Trap, we observed a growth retardation of C6 tumors for up to 14 days post-tumor cell injection, although tumors eventually progressed. In mice, tumors were detectable in all control groups by 14–17 days post-injection of glioma GL261 cells and progressed rapidly thereafter. In mice treated with rTMS prior to IGF-Trap administration, tumor growth was inhibited or delayed, although the tumors also eventually progressed. Conclusion: The results showed that rTMS could increase the anti-tumor effect of IGF-Trap during the early phases of tumor growth. Further optimization of the rTMS protocol is required to improve survival outcomes.

19 October 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
JNJessica Nickerson
Jessica Nickerson
SCStefanie Condon-Oldreive
Stefanie Condon-Oldreive
ETErica Tsang
Erica Tsang
GZGeorge Zogopoulos
George Zogopoulos
Rodney J. OuelletteRodney J. Ouellette
Rodney J. Ouellette
KLKen Leslie
Ken Leslie
Pancreatic cancer (PC) is among the most lethal malignancies with slower progress in overall survival and treatment options compared to other cancers. The 2025 Canadian National Pancreas Conference (NPC)—the third biennial event of its kind—was hosted by Craig’s Cause Pancreatic Cancer Society and the Baker Centre for Pancreatic Cancer in November 2025 in London, Ontario, co-organized by the Canadian Association of General Surgeons (CAGS) with accreditation through the Royal College of Physicians and Surgeons of Canada. The event brought together experts across healthcare disciplines as well as researchers, students, and allied professionals to discuss the latest advances in treatment and management of this complex disease. The conference featured presentations, workshops, and discussions on the current landscape of treatment and management of PC with an emphasis on the increasing significance of genomic sequencing, equitable care, and a multidisciplinary approach.